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Abstract: COVID-19 caused by a novel agent SARS-CoV-2 progressed to a pandemic condition and resulted in a major public health
concern worldwide, leading to social and economic issues at the same time. The pathogenesis of COVID-19 starts with the bonding of
the virus to ACE2 receptors expressed in many tissues, and the triggered excessive immune response plays a critical role in the course
of the disease. The cytokine storm that occurs upon excessive production of pro-inflammatory cytokines is considered responsible for
the severe progression of the disease and the organ damage. However, the accurate pathophysiological mechanism of the disease, which
progresses with various clinical presentations, is still substantially unknown. While various studies have been conducted on the effect
of genetic polymorphism on the course and severity of the disease, the presence of a significant effect has not been proven yet. The
clinical course of the disease is variable, with clinical representation ranging from 81% mild course to 14% severe course along with 5%
critical course in patients. Asymptomatic course is considered to be higher than expected, although its frequency is not known exactly.
Older adults and those with comorbidities are exposed to a more severe disease course. The disease progress with various symptoms,
such as fever, cough, dyspnea, malaise, myalgia, taste and smell dysfunctions, diarrhea, and headache. A range of complications (acute
respiratory distress syndrome, thromboembolic conditions, arrhythmia and cardiac events, secondary infections) could be seen during
the course of the disease. Varied laboratory tests are vital to determine these verity and prognosis of the disease, along with the condition
and exposure of the affected systems during thecourse of COVID-19.
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1. Introduction
The COVID-19 pandemic caused by SARS-CoV-2 virus
continues to be effective around the world. Although it
is a novel agent and disease with a background of nearly
5 months, the research studies conducted on this subject
continue intensively, and the information produced is
rapidly shared via open access publications.
This paper will discuss the pathogenesis, genetic
polymorphism, clinical and laboratory findings related to
COVID-19.
2. Pathogenesis
The pathogenesis of COVID-19 caused by SARS-CoV-2,
which is a novel virus, is being updated and evolving as
part of various discussions.
SARS-CoV-2 is mainly transmitted through respiratory
droplets and contact and potentially by fecal-oral routes. In
addition, the aerosols generated during some procedures,
particularly in hospitals, are another mode of transmission
[1].

SARS-COV-2 spike proteins bind to angiotensinconverting enzyme 2 (ACE2) receptors on the surface of
a target cell. The type II transmembrane serine protease
(TMPRSS2) binds to the ACE2 receptor and makes it
cleaved. In this proteolytic process, the spike protein is
activated and viral entry into the cell takes place [1,2].
It is reported that CD147 (a transmembrane
glycoprotein that belongs to the immunoglobulin
superfamily) is the other receptor bound by the virus;
CD147 exists in epithelial cells and is expressed at very
high levels in inflamed tissues, pathogen-infected cells and
tumor tissues [3].
For the pathogenesis of COVID-19, this is the very first
step of the complex pathogenesis process [1].
It is assumed that primary viral replication develops
in the mucosal epithelium of the upper respiratory tract
(nasal cavity and pharynx), with further multiplication in
lower respiratory tract and gastrointestinal mucosa, which
results in a mild viremia [1,4]. At this point, a small number
of infections are checked and remain asymptomatic [1]. A
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number of recent studies indicate that the asymptomatic
course may be at a higher rate [1,5].
The pathogenesis is basically described as binding of
the SARS-CoV2 to the receptors (ACE2) in the type II
pneumocytes in the lungs and its triggering of a cascade of
inflammation in the lower respiratory tract [1].
Some patients also exhibit nonrespiratory symptoms,
such as acute liver and heart injury, kidney failure
and diarrhea, which are indicative of multiple organ
involvement [6,7,8].
ACE2 is broadly expressed in nasal mucosa, bronchus,
lung, heart, esophagus, kidney, stomach, bladder, and
ileum, and all these human organs are vulnerable to
SARS-CoV-2 [1,2,9]. Recently, the potential pathogenicity
of SARS-CoV-2 to testicular tissues was also proposed,
which has raised concerns over fertility issues in young
patients [10]. Biophysical and structural evidence suggest
that SARS-CoV-2 S protein binds to human ACE2 with
10- to 20-fold higher affinity than SARS-CoV S protein
[1,11].
The critical steps of pathogenesis of the SARS-CoV-2
infection based on the data compiled to date are shown
in Figure.
It was suggested that 1 of the factors that determine the
clinical course of COVID-19 is associated with the viral
load transmitted to the person. In general, the disease is
more severe in people, who are exposed to higher risk of
viral load transmission, such as healthcare professionals.
It was reported that the COVID-19 patients having more
severe diseases, who should be admitted to intensive care
unit, had high a viral RNA load at 10 days and beyond,
after symptom onset. A mild clinical or asymptomatic
course is usually observed in patients infected with a lower
viral load; there are further contradictory reports on this
issue [1, 12,13].
The course of the disease is linked to the body’s immune
response to the virus and the patient’s comorbidities, apart
from the viral load. If the immune system is not activated,
the virus reproduces faster. If the immune system is
clearly activated, it causes a cytokine storm and induces a
multisystemic effect [1,14].
The development mechanisms of severe cases, other
than asymptomatic or mild clinical cases, during the
pathogenesis process will be summarized below.
Fast viral replication and cellular damage, virusinduced ACE2 downregulation and shedding and
antibody dependent enhancement (ADE) are responsible
for the aggressive inflammation caused by SARS-CoV-2
[1,15] (see Figure).
2.1. Immune response
The active host immune reaction, including innate
and adaptive immune to SARS-CoV-2, is essential for
controlling and resolving viral infection. Both innate

and adaptive immune cells are synergistically involved
in the antiviral response during infection. A considerable
increase in the number of leukocytes and neutrophils and
the neutrophil to lymphocyte ratio (NLR) was found in
severe cases than in mild cases [16].
Viral entry and cellular infection trigger the immune
response of the host cell, and the inflammatory cascade is
initiated by antigen-presenting cells (APC). The process
starts with ACP performing 2 functions: (1) presentation
of the foreign antigen to CD4 + -T-helper (Th1) cells and
(2) release of interleukin-12 to further stimulate Th1 cell.
Th1 cells stimulate CD8 + -T-killer (Tk) cells that will
target the cells containing foreign antigen. In addition,
activated Th1 cells stimulate B cells to produce antigenspecific antibodies[1].
The inflammatory process can accelerate the apoptosis
of lymphocytes while stimulating the synthesis of
neutrophils. This irregular response given by the immune
system and immunological abnormality may result in
conditions leading to death [1].
The studies carried out demonstrated that neutrophil
to lymphocyte ratio in patients with COVID-19 may be
a significant marker in explaining disease severity and
mortality [1].
It is not clear yet whether an immune response effective
against SARS-CoV-2 has developed. Several studies
showed the existence of a significant relationship between
the disease severity and the levels of proinflammatory
cytokines and subsets of immune cells. Immune
dysregulation and high levels of proinflammatory
cytokines were potentially suggested to be the root cause
of tissue damage during response to SARS-CoV-2 [1,16].
For COVID-19, the production of proinflammatory
cytokines and the jointly functioning innate and adaptive
immune response that makes CD4+/CD8+ T cells
activated are vital to control viral replication, restrain the
spread of virus and clear the infected cells [1,16].
It was suggested that survival from COVID-19 could
rely on the ability to replenish lymphocytes killed by the
virus. Therefore, the count of lymphocytes, especially of
CD4 cells, could serve as a clinical predictor of disease
severity and prognosis [17].
2.2. Antibody response and ADE
As with SARS, a small proportion of patients, especially
those who produce neutralizing antibodies early,
experience persistent inflammation, ARDS and sudden
death, while most patients survive the inflammatory
responses and clear the virus. For the SARS-CoV-2
infection, antibody-dependent enhancement (ADE) is
considered to be 1 of the potential underlying mechanisms
as in some cases of other viral infections [1]. Interaction of
FcR with the virus-anti-S protein neutralizing antibodies
(anti-S-IgG) complex may catalyze both inflammatory
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Mild viremia

Figure. The critical steps of pathogenesis of the SARS-CoV-2 infection [1]. ADE: Antibody-dependent enhancement; ACE2:
Angiotensin-convertingenzyme 2; RAS: Renin-angiotensin system; ARDS: Acute respiratory distress syndrome.

responses and persistent viral replication in the lungs [15].
2.3. Immune dysfunction
Peripheral CD4 and CD8 T cells were reduced and
hyperactivated in severe patients. In addition, high
concentrations of proinflammatory CD4 T cells and
cytotoxic granules CD8 T cells were identified, which
suggests antiviral immune responses and hyperactivation
of T cells. Furthermore, many studies indicate that
lymphopenia, a common feature of COVID-19 is a critical
factor regarding disease severity and mortality [1, 18, 19].
2.4. Cytokine storm
Cytokine storm is an extreme and severe reaction
(hyperreaction) given by the immune system, where large
amounts of cytokines are rapidly released into the systemic
circulation [1,15].
High levels of cytokines in critical COVID-19
patients are considered to be important in explaining
the pathogenesis of the disease due to the effect of the
inflammatory storm [16].
Exuberant inflammatory responses occur during
the clinical course of the SARS-CoV-2 infection,
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which subsequently results in uncontrolled pulmonary
inflammation. This is probably the leading cause of case
fatality [15].
The initial onset of rapid viral replication causes
mass epithelial and endothelial cell death and vascular
permeability, potentially triggering the production of
exuberant proinflammatory cytokines and chemokines
[20].
COVID-19 mainly targets the respiratory system; the
main pathogenesis is the resulting severe pneumonia,
RNAaemia and acute cardiac injury [6].
SARS-CoV-2 binds to the receptors in alveolar and
gastrointestinal epithelial cells and activates the innate and
adaptive immune system, leading to the secretion of a vast
number of cytokines, including IL-6 [21].
In some severe cases referred to intensive care units,
high levels of cytokines and chemokines were noted
in COVID-19 patients, such as IL1-β, IL1RA, IL7, IL8,
IL9, IL10, basic FGF2, GCSF, GMCSF, IFNγ, IP10,
MCP1, MIP1α, MIP1β, PDGFB, TNFα, and VEGFA
[18]. The markers related to hyperinflammation (hs-
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CRP, procalcitonin, IL-2R, IL-6, IL-8, IL-10, TNF-alpha,
inducible protein (IP10), monocyte chemoattractant
protein-1 (MCP1), macrophage inflammatory protein-1α
(MIP1A)) were noted significantly higher in patients who
died than survivors [22]. These cytokines and chemokines
are positively linked to the SARS-CoV-2 viral load [16].
The high level of IL-6 may be considered a marker of
severe disease or progressive disease [23].
IL-6 levels in admission are a predictor of the need
for mechanical ventilation [24]. In addition, those with
high IL-6 levels experience RNAaemia, with the longer
virus RNA spread [23-26]. RNAaemia is associated
with more severe clinical courses [25,26]. IL-6 induces
intracellular signaling, antibody secretion, acute phase
protein secretion, platelet formation with effect on
megakaryocytes, angiogenesis with increment in vascular
endothelial growth factor (VEGFR), mesenchymal cell
proliferation, and cardiomyopathy. Additionally, IL-6
plays a role in activating the complement and coagulation
system in DIC pathophysiology. For these properties, IL-6
is the key molecule for cytokine storm [21]. The increased
plasma level of IL-6 that is regarded a significant cytokine
contributing to MAS is noted in mild and severe patient
groups of COVID-19: severe patients have a significantly
higher level of IL-6 than mild patients or patients without
fever [16].
Excessive increase in inflammatory cytokines such
as IL-6, which may result in “cytokine storm”, is not only
likely to be a driver behind acute lung injury and ARDS,
but also may cause other tissue damage that progresses to
multiple organ failure (MOF). In addition, high levels of
interleukin 10 (IL-10) were noted in severe patients. It was
noted that this could be associated with the compensatory
antiinflammatory response syndrome (CARS) that may be
responsible for a greater number of secondary infections
(50%) and sepsis (100%) reported in survivors [27].
Tissue damage caused by the virus may induce
excessive production of proinflammatory cytokines,
and recruitment of proinflammatory macrophages and
granulocytes. This gives rise to the cytokine storm (CS)
referred to as macrophage activation syndrome (MAS) or
secondary hemophagocytic lymphohistiocytosis (sHLH),
thus causing further damage to tissues [1, 16].
Several mechanisms may contribute to hyperactivation
of monocyte-induced macrophages observed in patients
with COVID-19 [28]. The inflammatory response
resulting from excessive cytokine secretion observed with
the activation of T cells and monocytes/macrophages
increases vascular permeability, causing exudative
effusion in the alveoli and resulting in respiratory failure.
Cytokines play a key role in pathophysiology and clinical
findings. INF is secreted from activated T cells, which then
activates macrophages that produce proinflammatory and

antiinflammatory cytokines, such as IL-6, TNFα, IL-18,
IL-2, IL-1α, IL-1β and IL-10 [1,28 ].
The delayed production of type I interferon, which
results in enhanced cytopathic effects and increased
sensing of microbial threats, boosts the enhanced release
of monocyte chemoattractants by alveolar epithelial cells
(and probably further by macrophages and stromal cells),
giving rise to sustained recruitment of blood monocytes
into the lungs [1,28].
Monocytes distinctly change into proinflammatory
macrophages mediated by the activation of Janus
kinase (JAK), such as signal transducer and activator of
transcription (STAT) pathways. The activated natural killer
(NK) cells and T cells further stimulate the recruitment
and activation of monocyte-induced macrophages with
the help of the production of granulocyte-macrophage
colony-stimulating factor (GM-CSF), tumor necrosis
factor (TNF) and interferon-γ (IFNγ). Accumulation of
oxidized phospholipids (OxPLs) occurs in infected lungs,
which activates monocyte-induced macrophages through
the Toll-like receptor 4 (TLR4)–TRAF6–NF-κB pathway.
Virus sensing has the potential to trigger TLR7 activation
through the recognition of viral single-stranded RNA.
The expression of severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) entry receptors, which is
induced by type I interferons, causes the virus to reach
the cytoplasm of macrophages and to activate the NLRP3
inflammasome, giving rise to the secretion of mature
IL-1β and/or IL-18. IL-1β may enhance the activation
of monocyte-derived macrophages in an autocrine or
paracrine manner, but also may lead to reduction in type I
interferon production in infected lungs [28 ].
The activation of NLRP3 inflammasome in
macrophages, epithelial cells and even endothelial cells
results in the release of proinflammatory cytokines that
contribute to pathogenic inflammation responsible for the
severity of COVID-19 symptoms [28].
The interaction of Fcg receptors with antispike
protein IgG immune complexes may contribute to
the amplified inflammatory activation of monocyteinduced macrophages. The activated monocyte-induced
macrophages release large amounts of proinflammatory
cytokines and contribute to the COVID-19 cytokine storm
[28].
These conclusions show that SARS-CoV-2 is responsible
for immune irregularity resulting from the change in the
entire lymphocyte subset level, which may lead to cytokine
storm and further tissue damage, by inducing abnormal
cytokine and chemokine response[1,28].The excessive
inflammatory response caused by cytokine storm results
in severe disease course and aggravates the prognosis in
COVID-19[1,28].
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2.5. Acute respiratory distress syndrome (ARDS)
Earlier studies indicate that genetic vulnerability and
inflammatory cytokines are closely related to the
occurrence of ARDS. ACE2 is considered to be linked to
the development or outcome of over 40 candidate genes,
including interleukin 10 (IL-10), tumor necrosis factor
(TNF) and vascular-endothelial growth factor (VEGF)
[1,29].
The data from patients infected with SARS-CoV-2
indicated that severe cases characterized by a cytokine
storm inevitably progress to acute respiratory distress
syndrome (ARDS) [16].
In addition, the increased plasma level of IL-6 and IL-8
was shown to be associated with negative outcomes of
ARDS [1]. Considering pulmonary infiltration in patients
with ARDS, the large area of lung injury (≥50%) is closely
related to the increased level of IL-6 and the subset of
lymphocytes in the peripheral blood [1,16].
Pulmonary damage such as ARDS is noted in 50%
of the patients developing MAS. During the course of
COVID-19, a cytokine profile resembling MAS is also
associated with enhanced disease severity. These patients
were noted for the increased level of serum CRP, lactate
dehydrogenase (LDH) ferritin, serum creatinine, creatine
kinase (CK) and IL-6 and D-dimer [1,16].
2.6. ACE2 downregulation and shedding
It was suggested that the loss of pulmonary ACE2 function
is related to acute lung injury due to the potential of ACE2
downregulation and shedding to cause dysfunction of the
renin-angiotensin system (RAS) and to further enhance
inflammation and cause vascular permeability [1,15].
Fast viral replication and cellular damage, virusinduced ACE2 downregulation and shedding and antibody
dependent enhancement (ADE) are responsible for the
aggressive inflammation caused by SARS-CoV-2 [1,15].
Initially, rapid viral replication causes mass epithelial
and endothelial cell death and vascular permeability,
potentially triggering the production of exuberant
proinflammatory cytokines and chemokines [1,15].
2.7. Other effects in pathogenesis:
Effects on the coagulation system:
Activation and interactions of macrophages, monocytes,
endothelial cells, platelets and lymphocytes play a critical
role in the procoagulant effect of viral infections [1,30].
Increased venous and arterial thrombosis (including
small vessels) resulting from the overactivation of the
coagulation system are shown to affect the clinical course
adversely [30,31].
Irregularity of the coagulation cascade, followed by the
formation of intraalveolar or systemic fibrin clots, is 1 of
the distinct symptoms of severe respiratory disease caused
by COVID-19 [30,31].
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Both thrombocytopenia and high D-dimer level can be
explained by overactivation of the coagulation cascade and
platelets. Viral infections cause the systemic inflammatory
response and result in an imbalance between procoagulant
and anticoagulant homeostatic mechanisms. There are
many pathogenetic mechanisms, including endothelial
dysfunction, von Willebrand factor elevation, Toll-like
receptor activation and tissue-factor pathway activation.
Dysfunction of endothelial cells induced by infection
results in excessive thrombin production and fibrinolysis
inhibition, which indicates hypercoagulability in a
COVID-19 infected patient [1,30,31].
COVID-19 may make patients prone to both venous
and arterial thromboembolism owing to excessive
inflammation, hypoxia, immobilization and DIC. Acute
pulmonary embolism (PE), deep-vein thrombosis (DVT),
ischemic stroke, myocardial infarction or systemic
arterial embolism are frequently noted in these patients.
Actual studies have shown that patients with severe
COVID-19 are usually complicated by coagulopathy,
with DIC accompanying most deaths. Patients severely
infected with COVID-19 may develop DIC through the
activation of fulminant coagulation, leading to depletion
of common microvascular thrombosis and coagulation
factors. As a consequence, the presentation turns out to
be thrombocytopenia, prolonged PT/INR, PTT, D-dimer
elevation and reduced fibrinogen level. Cystocytes can be
observed in the peripheral smear of patients [30,31].
The prolonged immobility of patients or the long
inpatient treatment duration increases the risk of venous
thromboembolism in severe COVID-19 disease. The
RAAS pathway is activated upon binding of the virus
to ACE2 and leading to reduced enzyme expression.
RAAS activation bears the risk of platelet adhesion and
aggregation and, theoretically, of pulmonary embolism,
pulmonary hypertension and fibrosis. The increased level
of lactate dehydrogenase, ferritin, C-reactive protein,
D-dimer and interleukin seen in COVID-19 indicates
that the disease predisposes to a proinflammatory and
hypercoagulable condition [31,32].
The recently emerging various data, some part of
which are described above, support the argument that
patients infected with the SARS-CoV-2 virus are at risk of
developing disseminated intravascular coagulation (DIC)
[33,34].
Cardiac effects
Cardiac physiopathology: 1) failure of the limited
cardiac reserve to meet the increased metabolic needs
due to infection, 2) capacity of viral infections to trigger
acute coronary syndromes, arrhythmias and heart failure
(this presentation is associated with the localized vascular
inflammation at arterial plaque level as well as the severity
of needs imbalance, and systemic inflammatory response)
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and 3) rapid and severe downregulation developing in
myocardial and pulmonary ACE2 pathways enhance the
risk of myocardial injury. In addition, cytokine storm,
severe immunopathological cases mediated by interferon,
and hypoxemia associated with respiratory dysfunction
act on myocardial injury [22, 35].
In the systematic review and meta-analysis, there
is an increased risk of acute cardiac/myocardial injury
associated with a more severe COVID-19 infection
(exaggerated inflammatory response), and this acute
cardiac injury is associated with death [36].
Effects on the gastrointestinal system
Patient reports and biopsies showed that the infection
may also affect the gastrointestinal system that is rich
in ACE2 receptors. Diarrhea is noted in approximately
20% of the patients. The mechanism is not fully known.
Viral infection alters intestinal permeability, leading to
enterocyte malabsorption [37].
Additionally, the proposition was that intestinal ACE2
is involved in the uptake of dietary amino acids, regulates
the expression of antimicrobial peptides and stimulates
the homeostasis of gut microbiome [37,38]. Mouse models
demonstrated that the presence of ACE2 alterations is
linked to colitis, which indicates that virus activity is likely
to result in enzyme modifications and to enhance the
vulnerability to intestinal inflammation and diarrhea [38].
Liver damage
The cause of liver damage induced by COVID-19 is not
fully understood, and the elevation of liver enzymes may
result from cytokine storm or drug-induced liver damage.
The SARS-CoV-2 infection is considered to be capable
of infecting endothelial cells in the bile duct of the liver
and causing inflammatory damage to the liver; the cellular
damage in the liver may be the direct consequence of viral
infection [39].
Kidney damage
Kidney damage is common in very severe cases, and
contributes to mortality. The virus may attack the kidneys
directly or kidney damage may be a part of systemic
conditions such as low blood pressure [40].
Neurological involvement
The conditions of stroke, epilepsy and encephalitis
noted in some patients with COVID-19 E indicate that the
virus also affects nerve cells. The olfactory nerve endings
of some patients are affected, and they completely lose
their sense of smell. Coronaviruses can cause damage to
the nervous system through direct infection pathways
(bloodstream and neuronal pathways), hypoxia (enhanced
anaerobic metabolism and acid metabolites), immune
injury, ACE2 and other mechanisms. Additionally,
coronaviruses cause hypoxia as they attack the lung tissue
[1,41].
Coronaviruses can penetrate the nervous system
directly through the olfactory nerve and also cause

neurological disorders (infectious toxic encephalopathy,
viral encephalitis, acute cerebrovascular disease) by
penetrating through neuronal pathways [42].
2.8. Conclusion
The pathogenesis is summarized based on the available
information given above. There are still several unknown
and controversial issues regarding the pathogenesis
of COVID-19, although a considerable amount of
information has been obtained in a short time in this
respect.
Both the viral particle and the virus-induced
exaggerated immune response play an important role in
the pathogenesis of COVID-19. The cytokine storm that
occurs upon excessive production of proinflammatory
cytokines is considered responsible for the severe
progression of the disease and the organ damage. However,
the accurate pathophysiological mechanism of the disease,
which progresses with various clinical presentations, is still
substantially unknown. Having an understanding of the
pathogenesis will bring benefits for identifying prognostic
biomarkers and developing therapies for patients at high
risk of developing ARDS or multiple organ failure.
3. Polymorphisms and infectious diseases
With the completion of the human genome project and
the discovery of new technologies, the variants, such as
short tandem repeat (STR), variable number tandem
repeat (VNTR) and single nucleotide polymorphism
(SNP), which are more common than mutations in the
genome, began to be identified more rapidly. Today,
many genetic polymorphisms are known to be effective
in pathways that play an important role in the attachment
of the microbiological agent to the host cell, the host’s
resistance to disease, susceptibility to disease and severity
of diseases. This is supported by community-based genetic
epidemiological analyses. For a long time, the best known
example is the protection provided by HbS against the
malaria caused by falciparum [43]. A variant in the Duffy
antigen gene promoter region inhibits the expression of
the protein bound by the Plasmodium vivax Duffy binding
protein on the erythrocyte surface [44]. Amongst others,
the best documented genetic polymorphism regulating
disease susceptibility is the CCR5-Δ32 HIV resistance
allele [45]. To enter the cell, HIV-1 uses several chemokine
co-receptors such as CCR5. Depending on whether this
polymorphism is homozygous or heterozygous, the disease
does not occur or progression of the disease is delayed.
Humanity has been exposed to significant epidemics of
coronavirus types over the past 20 years. The first and third
of these are caused by the severe acute respiratory syndrome
(SARS), SARS-coronavirus (SARS-CoV) and SARSCoV-2 (COVID-19). Angiotensin-converting enzyme 2
(ACE2) is the cellular receptor for both coronavirus types.
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There are some theories of ACE2 gene polymorphisms
and low expression levels to protect the host against and
to fight these viruses [46]. According to the publication by
Stawiski et al., although human ACE2 variants S19P, I21V,
E23K, K26R, T27A, N64K, T92I, Q102P and H378R are
predicted to increase susceptibility, especially T92I, part of
a consensus NxS/T N-glycosylation motif and other ACE2
variants K31R, N33I, H34R, E35K, E37K, D38V, Y50F,
N51S, M62V, K68E, F72V, Y83H, G326E, G352V,D355N,
Q388L and D509Y are putative protective variants
predicted to show decreased binding to SARS-CoV-2
S-protein [47]. In Italy, 1 of the countries having highest
mortality rate from SARS-CoV-2 infections, no significant
correlation was found between the disease severity and
gender susceptibility of ACE2 [48]. However, in the same
study, TMPRSS2 levels and genetic variants proved to be
possible candidate disease modulators, contributing to
the observed epidemiological data among Italian patients.
It has been reported that not only the ACE2 gene, but
also the ACE1 gene may be important for SARS-CoV-2
infections in terms of affecting the clinical course [49].
However, according to the gnomAD database, there is no
significant difference in frequencies of the 6 ACE2 variants
(rs200180615, rs140473595, rs199951323, rs147311723,
rs149039346, rs73635825) mentioned in the literature
[50] among South Asian, East Asian, African, Latin,
Ashkenazi Jews, European (Finnish and non-Finnish)
races. At the same time, based on the data from İstanbul
Medipol University Genetic Diagnosis Center, there is
no significant difference in frequency of these variants
when comparing between Turkish society and Iranome
with gnomAD databases (see Table 1). ICAM-3, OAS1
and MxA gene polymorphisms are also among other
candidate factors associated with the protection against

SARS-CoV infections [51,52]. The second epidemic is
Middle East respiratory syndrome coronavirus (MERSCoV), which emerged in Saudi Arabia in 2012 and spread
to 27 countries. The MERS-CoV spike (S) glycoprotein
mediates viral entry into target cells [53]. Some genetic
polymorphisms that adversely affect the entry of the
MERS-CoV virus into the cell have been reported to be
present in the DPP4.
Genetic polymorphisms are used in medicine for many
purposes today. As the mechanisms caused by genetic
polymorphisms are better understood, this is expected to
allow for new treatments and discover of preventive drugs.
4. Clinical features
The novel coronavirus (COVID-19) infection is a
respiratory system infection caused by SARS-CoV-2.
This novel infectious agent, which was striking for the
successive pneumonia cases occurring in Wuhan province
of China in December 2019, is a betacoronavirus that is
closely correlated to the SARS virus in genetic terms [54].
COVID-19 is a highly contagious infection. Various
studies indicated the basic reproduction number (R0) as
2.6 to 4.7. When all 3 coronavirus infections leading to
epidemic are compared, the mean age and sex distribution
is similar. Table 2 shows the comparison of COVID-19
with SARS and MERS. Disease burden doubles every 7.7
days and 1 person infects an average of 2 to 3 people [55–
58].
The incubation duration of COVID-19 infection ranges
from 2 to 14 days, and various studies demonstrate that
symptoms are seen within an average of 4 to 7 days [56].
The frequency of asymptomatic infection is uncertain.
The initial data from China indicate this frequency as
1%–2%, while a modeling study suggests that this ratio

Table 1. Frequency of ACE2 variants in different population.
Frequency
Population

rs200180615

rs140473595

rs199951323

rs147311723

rs149039346

rs73635825

East Asian

0.0002177

0

0.00007948

0

0

0

South Asian

0.00005322

0

0

0

0.005278

0

African

0

0

0

0.0143

0.005836

0.003323

Latino

0

0

0

0.0004848

0.00003584

0

Ashkenazi Jewish

0

0

0

0

0

0

European (Finnish)

0

0

0

0

0

0

European (Non-Finnish)

0

0.00004746

0

0.00331

0.00002164

0

Iranome

0

0

0

0

0

0

Turkish*

0

0

0

0

0

0

*The data were taken from the İstanbul Medipol University Genetic Diagnosis Center database.
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is minimum 18% [5,55]. Additionally, abnormal lung
tomography findings were found in 67% of asymptomatic
cases identified by contact tracing [59].
The recovery takes about 2 weeks in mild cases and 3
to 6 weeks in severe cases. The duration from the onset
of symptoms to death ranges from 2 to 8 weeks. Virus
transmission peaks at the early stage of the disease.
Transmission starts 24 to 48 h before symptoms and
generally takes 7 to 12 days in mild/moderate cases and >
2 weeks in severe cases. PCR might be positive even after
the patient is relieved of symptoms [60,61].
The COVID-19 clinical presentation is mild, moderate,
severe and critical (Table 3) [62]. 81% of the confirmed
cases in China were mild, while 14% (accompanied by
hypoxemia, dyspnea and tachypnea) involved severe
disease that required hospitalization and oxygen therapy.
However, 5% were critical (with respiratory failure, septic
shock and/or multiple organ dysfunction) and required
admission to intensive care units [54]. No pneumonia was
found in approximately 40% of the cases. In mild cases,
the clinical presentation is dominated by the symptoms
of viral upper respiratory tract infection, with likely
symptoms of mild pneumonia in some cases. There are
some further symptoms, such as low-grade fever, nasal

congestion, sore throat, headache, dry cough, fatigue and
muscle pain. However, mild cases may still rapidly become
critical. The conditions in moderate cases may worsen
more frequently, therefore this group of patients should be
monitored by exercising greater care [60–62]. The rapidly
developing ARDS, septic shock, metabolic acidosis,
coagulation dysfunction and multiple organ failure (acute
kidney damage, cardiac damage, etc.) are important in
critical cases [5,57].
Renal damage may occur depending on the virus
or antivirals. Additionally, the virus may result in liver
damage and testicular damage at varying levels [62].
Acute respiratory distress syndrome (ARDS) is
diagnosed on a mild, moderate or critical basis in the
intensive care setting considering PaO2/FiO2 parameters
used to evaluate hypoxia as well as given the manifestation
of the new-onset or worsening respiratory failure in the
patient. In this case, it is better to perform diagnosis using
chest X-ray, lung CT scan and ultrasound [60,61].
The clinical syndromes related to COVID-19, which
are published and updated, as required, by the World
Health Organization to help handling and monitoring of
critical cases as clinical information about cases piles up,
are exactly shown in Table 4 [1].

Table 2. Comparison of some characteristics between SARS-CoV, SARS- CoV-2, and MERS-CoV.
(Adapted from resources 5, 57 and 58)
Outbreaks

Confirmed case
Mean age
male (%)

Ro

Case fatality
rate (%)

Mean incubation
period

COVID-19

67

55.5

2-3

2.3

5–6 days (2–14)

SARS -CoV

47

41.3

2–5

9.6

4–6 days

MERS

53

53

1

34.4

5 day

*SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2; SARS-CoV: Severe acute
respiratory syndrome coronavirus; MERS- CoV: Middle East respiratory syndrome coronavirus;
R0: Reproduction number.
Table 3. Clinical types of COVID-19 [62].
Mild

The clinical symptoms were mild, and there was no or mild sign of pneumonia on imaging

Moderate

Showing fever and respiratory symptoms with radiological findings of pneumonia.

Severe

In accordance with any of the following:
a. Shortness of breath (RR ≧ 30 breaths/min);
b. In resting state, oxygen saturation ≤ 93%;
c. Arterial partial pressure of oxygen (PaO2)/fraction of inspired oxygen (FiO2) ≦ 300 mmHg (l mmHg = 0.133kPa).
d. Cases with chest imaging showed obvious lesion progression more than 50% within 24–48 h.

Critical

One of the following:
a. Respiratory failure, requiring mechanical ventilation;
b. Septic shock;
c. Multiple organ failure (With other organ failure that requires ICU care.)
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Table 4. Clinical syndromes associated with COVID-19.

Mild illness

Pneumonia

Severe
pneumonia

Acute
respiratory
distress
syndrome
(ARDS)

Sepsis

Septic
shock
(5, 6)

Patients uncomplicated upper respiratory tract viral infection may have nonspecific symptoms such as fever, fatigue, cough (with or
without sputum production), anorexia, malaise, muscle pain, sore throat, dyspnea, nasal congestion, or headache. Rarely, patients may
also present with diarrhea, nausea, and vomiting. The elderly and immunosuppressed may present with atypical symptoms. Symptoms
due to physiologic adaptations of pregnancy or adverse pregnancy events, such as dyspnea, fever, GI-symptoms or fatigue, may overlap
with COVID- 19 symptoms.
Adult with pneumonia but no signs of severe pneumonia and no need for supplemental oxygen. Child with nonsevere pneumonia who
has cough or difficulty breathing + fast breathing: fast breathing (in breaths/min): < 2 months: ≥ 60; 2–11 months: ≥ 50; 1–5 years: ≥
40, and no signs of severe pneumonia.
Adolescent or adult: fever or suspected respiratory infection, plus one of the following: respiratory rate > 30 breaths/min; severe
respiratory distress; or SpO2 ≤ 93% on room air). Child with cough or difficulty in breathing, plus at least 1 of the following: central
cyanosis or SpO2 < 90%; severe respiratory distress (e.g., grunting, very severe chest indrawing); signs of pneumonia with a general
danger sign: inability to breastfeed or drink, lethargy or unconsciousness, or convulsions (15). Other signs of pneumonia may be
present: chest indrawing, fast breathing (in breaths/min): < 2 months: ≥ 60; 2–11 months: ≥ 50; 1–5 years: ≥ 40. While the diagnosis is
made on clinical grounds; chest imaging may identify or exclude some pulmonary complications.
Onset: within 1 week of a known clinical insult or new or worsening respiratory symptoms. Chest imaging (radiograph, CT scan, or
lung ultrasound): bilateral opacities, not fully explained by volume
overload, lobar or lung collapse, or nodules. Origin of pulmonary infiltrates: respiratory failure not fully explained by cardiac failure
or fluid overload. Need objective assessment (e.g., echocardiography) to exclude hydrostatic cause of infiltrates/edema if no risk factor
present. Oxygenation impairment in adults:
· Mild ARDS: 200 mmHg < PaO2/FiO2a ≤ 300 mmHg (with PEEP or CPAP ≥ 5 cmH2O, ornon-ventilated)
· Moderate ARDS: 100 mmHg < PaO2/FiO2 ≤ 200 mmHg (with PEEP ≥ 5 cmH2O, or nonventilated)
· Severe ARDS: PaO2/FiO2 ≤ 100 mmHg (with PEEP ≥ 5 cmH2O, or nonventilated)
· When PaO2 is not available, SpO2/FiO2 ≤ 315 suggests ARDS (including in nonventilated patients). Oxygenation impairment in
children: note OI = Oxygenation Index and OSI = Oxygenation Index using SpO2. Use PaO2-based metric when available. If PaO2
not available, wean FiO2 to maintain SpO2 ≤ 97% to calculate OSI or SpO2/FiO2 ratio:
Bilevel (NIV or CPAP) ≥ 5 cmH2O via full face mask: PaO2/FiO2 ≤ 300 mmHg or SpO2/FiO2 ≤ 264
Mild ARDS (invasively ventilated): 4 ≤ OI < 8 or 5 ≤ OSI < 7.5
Moderate ARDS (invasively ventilated): 8 ≤ OI < 16 or 7.5 ≤ OSI < 12.3 Severe ARDS (invasively ventilated): OI ≥ 16 or OSI ≥ 12.3.
Need objective assessment (e.g., echocardiography) to exclude hydrostatic cause of infiltrates/edema if no risk factor
present. Oxygenation impairment in adults:
· Mild ARDS: 200 mmHg < PaO2/FiO2a ≤ 300 mmHg (with PEEP or CPAP ≥ 5 cmH2O, ornon-ventilated)
· Moderate ARDS: 100 mmHg < PaO2/FiO2 ≤ 200 mmHg (with PEEP ≥ 5 cmH2O, or nonventilated)
· Severe ARDS: PaO2/FiO2 ≤ 100 mmHg (with PEEP ≥ 5 cmH2O, or nonventilated)
· When PaO2 is not available, SpO2/FiO2 ≤ 315 suggests ARDS (including in nonventilated patients). Oxygenation impairment in
children: note OI = Oxygenation Index and OSI = Oxygenation Index using SpO2. Use PaO2-based metric when available. If PaO2
not available, wean FiO2 to maintain SpO2 ≤ 97% to calculate OSI or SpO2/FiO2 ratio:
Bilevel (NIV or CPAP) ≥ 5 cmH2O via full face mask: PaO2/FiO2 ≤ 300 mmHg or SpO2/FiO2 ≤ 264
Mild ARDS (invasively ventilated): 4 ≤ OI < 8 or 5 ≤ OSI < 7.5
Moderate ARDS (invasively ventilated): 8 ≤ OI < 16 or 7.5 ≤ OSI < 12.3 Severe ARDS (invasively ventilated): OI ≥ 16 or OSI ≥ 12.3.
Adults: life-threatening organ dysfunction caused by a dysregulated host response to suspected or proven infection. bSigns of organ
dysfunction include: altered mental status, difficult or fast breathing, low oxygen saturation, reduced urine output (5,20), fast heart
rate, weak pulse, cold extremities or low blood pressure, skin mottling, or laboratory evidence of coagulopathy, thrombocytopenia,
acidosis, high lactate, or hyperbilirubinemia. Children: suspected or proven infection and ≥ 2 age-based systemic inflammatory
response syndrome criteria, of which 1 must be abnormal temperature or white blood cell count.
Adults: persisting hypotension despite volume resuscitation, requiring vasopressors to maintain MAP MAP ≥ 65 mmHg and serum
lactate level > 2 mmol/L. Children: any hypotension (SBP < 5th centile or > 2 SD below normal for age) or 2 or 3 of the following:
altered mental state; tachycardia or bradycardia (HR < 90 bpm or > 160 bpm in infants and HR < 70 bpm or > 150 bpm in children);
prolonged capillary refill (> 2 sec) or feeble pulse; tachypnea; mottled or cool skin or petechial or purpuric rash; increased lactate;
oliguria; hyperthermia or hypothermia.

aIf altitude is higher than 1000 m, then correction factor should be calculated as follows: PaO2/FiO2 × barometric pressure/760.
b The SOFA score ranges from 0 to 24 and includes points related to 6 organ systems: respiratory (hypoxemia defined by low PaO2/FiO2);
coagulation (low platelets); liver (high bilirubin); cardiovascular (hypotension); central nervous system (low level of consciousness
defined by Glasgow Coma Scale); and renal (low urine output or high creatinine). Sepsis is defined by an increase in the sepsis-related
SOFA score of ≥ 2 points. Assume the baseline score is 0 if data are not available (22).
ARI: Acute respiratory infection; BP: Blood pressure; bpm: Beats/minute; CPAP: Continuous positive airway pressure; FiO2: Fraction
of inspired oxygen; MAP: Mean arterial pressure; NIV: Noninvasive ventilation; OI: Oxygenation index; OSI: Oxygenation index using
SpO2; PaO2: Partial pressure of oxygen; PEEP: Positive end-expiratory pressure; SBP: Systolic blood pressure; SD: Standard deviation;
SIRS: Systemic inflammatory response syndrome; SOFA: Sequential organ failure assessment; SpO2: Oxygen saturation.
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With the occurrence of COVID-19 outbreak, many
series of cases were and are still continuously shared. As
in SARS and MERS cases, the most common symptoms
are fever and cough that often affect the lower respiratory
system. Some of the case series to date are summarized
in Table 5. Distinct symptoms are > 90% fever, 75% dry
cough and 70% fatigue, followed by dyspnea developing in
half of the patients 1 week later. Severe or critical patients
may have low- or moderate-grade fever or no fever. Fatigue
and myalgia were noted in > 40% of the cases. Runny
nose, nasal congestion and other upper respiratory tract
symptoms are less common (4%–6%). Additionally, there
are some other symptoms, such as headache, dizziness,
loss of appetite, anosmia and ageusia, sore throat,
nausea, stomachache, and cough with sputum. While
diarrhea was lower in the first series of cases (2%–3%),
it was reported to range from 10% to 14% in subsequent
cases. This suggests the probability of potential fecal-oral
transmission [6,7,33,63–66].
In Italy, 96.5% of the patients presented due to acute
respiratory distress. This was followed by acute kidney
failure with 29.2%, along with 10.4% acute cardiac injury
and 8.5% superinfection. The most common symptoms
found during presentation were fever and dyspnea (76%
and %73, respectively). 40% of the patients had cough.
No symptom was found in 5.7% of the patients [56]. The
loss of smell and taste, which was unidentified by initial
data from China, were reported to be seen in Italy by 34%
collectively and 19% individually [67].
Patients present to the hospital on day 4 from initial
symptoms on average, whereas mild respiratory distress
develops on day 5. From the onset of symptoms,
hospitalization takes an average of 7 days (4–18) and
respiratory distress occurs on day 8 on average (5–13)
and ARDS on day 9 on average1 [6,60–64]. Mechanical
ventilation is required on day 10.5 on average (7.0–14.00)
[5].
Most patients have a good prognosis. Pediatric patients
have mild symptoms. The course of the disease in pregnant
women is similar to that in people of the same age group.
No intrauterine transmission could be proven to date
[60,61].
The COVID-19 infection has a low mortality rate
compared to severe acute respiratory syndrome (SARS)
and Middle East respiratory syndrome (MERS) (9.60% and
34.4%, respectively). In proven cases, the case-fatality rate
is reported to be 2.3%–2.6% [5,54,58,59]. However, this rate
remains uncertain. There are differences between regions

of China, while the rates pertaining to different countries
in the world are just emerging. This ratio may be affected
by many factors, such as early diagnosis, early therapy and
healthcare access [54]. Most of the patients who died are
middle-aged and elderly people with comorbidities. No
deaths occurred in the group aged younger than 9 years.
However, the fatality rate among people aged 70 to 79 years
is 8%. No deaths were reported in relation to nonsevere
cases in China [54]. The case-fatality rate is 0.9% among
patients without any comorbidity. Nearly 50% of the
patients have one or more comorbidities. The case-fatality
rate is higher among elderly people (aged ≥ 60 years) and
people with comorbidities as follows: 14.8% ≥ 80 years,
10.5% cardiovascular disease, 7.3% diabetes, 6.3% chronic
lung disease, 6.0% hypertension and 5.6% cancer. This rate
is 0.9% among patients without any comorbidities. On the
other hand, the case-fatality rate among critical patients is
very high at 49.0% [54]. Even if the data provided by CDC
is limited, CDC considered obesity (body mass index ≥ 40)
and liver disease in the risk group2
The ratio of patients who died of COVID-19 infection
in Italy, which is 1 of the countries with the highest number
of deaths in the world, by age range is 42.2% for people
aged between 80 to 89 years and 32.4% for people aged
between 70 to 79 years. On the other hand, the rate of
deaths under the age of 70 years is lower (8.4% for the age
range from 60 to 69 years and 2.8% for the age range from
50 to 59 years). Death was more common among males
(70.6% in males compared to 29.4% in females) [56].
In Italy having many elderly deaths, approximately
2/3 of the cases accompanied by underlying diseases,
such as diabetes, cardiovascular diseases or cancer, and
smoking history verified the initial information obtained
in China. Comorbidities result in both challenges to
diagnosis and worsening of the condition. Considering
comorbidities in 3,200 positive tested patients who died
in Italy, 75.2% of those patients had ≥ 2 comorbidities
found as follows: 73.5% hypertension, 33.9% diabetes
30.1% ischemic heart disease, 22% atrial fibrillation, 20%
chronic kidney failure, 19.5% active cancer in the past 5
years, 13.7% chronic obstructive pulmonary disease, 11%
9 dementia, 11.2% stroke, and 3.7% chronic liver disease.
Prior to hospitalization, 36% of the patients followed ACEinhibitor therapy and 16% angiotensin receptor blockers
(ARBs) therapy [56].
101 patients diagnosed in an elderly care home in the
United States were aged 83 years on average, and 94%
had an underlying chronic disease. The case-fatality ratio

World Health Organization (2020). Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected: interim
guidance 13 March 2020 [online]. Website https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/patient-management
[accessed 28 March 2020].
1

Centers for Disease Control and Prevention (2020). People who are at higher risk for severe illness [online]. Website https://www.cdc.gov/
coronavirus/2019-ncov/need-extra-precautions/people-at-higher-risk.html [accessed 01 April 2020].
2
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55.5 ± 13.1

100%

*Ground glass opacity
(GGO), 77%; GGO
with reticular and/ or
interlobular septal
thickening%; GGO
Multiple mottling and
Radiographic evidence of with consolidation
ground glass opacity,
pneumonia
59%; Consolidation
14%); pneumothorax 1%
55%; Air bronchogram
80%; Reticulation 22%;
pleural effusion 8%;
Pericardial effusion 6%;
Lymphadenopathy 6%

41, prospective, 32%
admitted ICU

All

-

73%

66%

7.0 (.4.0–8.0)

95%

Bilateral ground glass
opacity, 98%

Suspected cases (%)

Asymptomatic patients
(%)

49 (41–58)

Confirmed cases (%)

Age, mean (IQR) or
mean ± SD, years

Sex, male

Exposure history

The mean duration
from onset of
symptoms to hospital
admission days**

Abnormal X-ray and
CT findings

X-ray and CT findings

NA

49%

68%

100%

99 with pneumonia
, retrospective, 23 %
admitted ICU

100%

NA

Before 1 Jan mean 12,5
days(95% CI, 10.3 to
14.8) Between 1–11 Jan
mean 9,1 days (95% CI,
8.6 to 9.7)
NA

98%

49%

49 ± 16

-

-

All

51 with pneumonia,

55%

66%

56 (26–82)

NA

NA

NA

425 with pneumonia

Jan 20–Jan 27, 2020

Total patients,
characteristics of
patients

Jan 22, 2020

Jan 1–Jan 20, 2020

Dec 16, 2019 – Jan 2 ,
2020

Song et al
[65]

Study time

Li et al
[64]

Chen et al
[63]

Huang et al
[6]

Author

Table 5. Clinical characteristics of Coronavirus Diseases ( COVID-19).

Jan 1–Jan 28, 2020

Wang et al
[7]

NA

100%

9,5 ( 7.0–12.5)

33%

67%

59.7 (SD13,3)

-

-

All

Ground glass opacity
100%

100%

7.0 (4.0–8.0); onset
of symptom to ICU
admission 10 (6–12)

8.7%

54.3%

56 (42–68)

-

-

All

138 with pneumonia,
52,
26 % admitted ICU,
critically ill adult patients Presumed humanwith pneumonia
to-human hospitalassociated transmission
41%

Late Dec, 2019 –Jan 26
, 2020

Yang et al
[66]

Ground-glass opacity,
56.4%; bilateral patchy
shadowing, 51.8%; Local
patchy shadowing, 41.9%;
Interstitialabnormalities,
14.7%

86.2%

NA

All

58.1%

47 (IQR 35 to 58)

-

-

All

1099 patients, 5% admitted
ICU (nonsevere 2.4% and
severe 19.1%)

Dec 2019 – Jan 29, 2020

Guan et al. et al [33]
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Total 51% including
Cardiovascular and
cerebrovascular diseases,
40%; Digestive system
disease , 11%; Endocrine
system disease(Diabetes)
,13%; others , 3%

Total 32% including
Diabetes, 20%;
Hypertension, 15%;
Cardiovascular disease,
15%; Chronic obstructive
pulmonary disease,
2%; Malignancy, 2%;
Chronic liver disease, 2%

68%

15%

Complications

Comorbidities

Discharged

Dead

NA

NA

NA

NA

Total 22% including
diabetes, hy- pertension,
chronic liver disease,
chronic obstructive
NA
pulmonary disease, and
cardiac disease; cigarette
smokers 7%

NA

61.5%**

NA

4.3%

34.1%

Total 46.4% including
Hypertension , 31.2%;
Cardiovascular disease
, 14.5%; Diabetes ,
10.1%; Malignancy ,
7.2%; Cerebrovascular
disease , 5.1%; COPD,
2.9%; Chronic kidney
disease 2.9%; Chronic
liver disease , 2.9%; HIV
infection , 1.4%
Chronic medical
illness 40%including
Chronic cardiac
disease, 10%; Chronic
pulmonary disease,
8%; Cerebrovascular
disease 13.5%; Diabetes
17%; Malignancy 4%;
Smoking, 4; others 4%

1.4 %

5% ( 93.6% hospitalized)

At least one coexisting
illness, 23.7%;
Hypertension , 15%;
Diabetes 7.4%; Coronary
heart disease , 2.5%;
Cerebrovascular disease,
1.2%; Chronic obstructive
pulmonary disease, 1.1%;
others 3.9%;Smoker ,
14.5%

(nonsevere and severe)
Septic shock , 1.1% (0.1%Shock, 8.7%; Acute
6,4%); Acute respiratory
cardiac injury, 7.2%;
distress syndrome , 3.4%
Arrhythmia, 16.7%;
(1.1%-15.6); Acute kidney
ARDS, 19.6%; AKI, 3.6%
injury , 0.5%
(0.1%–2.9%)

ARDS, 67%; Acute
kidney injury, 29%;
Cardiac injury, 23%;
Liver dysfunction,
29%; Hyperglycemia
, 35%; Hospitalacquired pneumonia
13.5%; Gastrointestinal
hemorrhage , 4%;
Pneumothorax
,2%; Hospital acquired
infections 13.5%
including Bacteremia
and pulmonary infection
2%; Urinary tract
infection , 2%

Fever ,43.8 % on admission
and 88.7% during
Fever, 96%;Cough,
Fever, 98.6%; Fatigue,
hospitalization; Cough,
47%; Phlegm, 20%;
69.6%; Dry cough, 59.4%; 67.8%; Fatigue
Fever, 98%; Cough,
Myalgia or fatigue,
Anorexia, 39.9%; Myalgia, , 38.1%; Sputum
77%; Dyspnea, 63.5%;
31%; Headache and
34.8%; Dyspnea, 31.2%; production, 33.7%;
Myalgia, 11.5%; Malaise,
dizziness, 16%; Dyspnea
Expectoration, 26.8%;
Shortness of breath,
35%; Rhinorrhea,
or chest pain,14%;
Pharyngalgia, 17.4%;
18.7%; Myalgia or
6%; Headache,
Loss of appetite,18%);
Diarrhea, 10.1%;Nausea, arthralgia, 14.9%; Sore
6%; Vomiting,4%;
Diarrhea ,10%; Stuffy
14 (10.1%) Dizziness,
throat , 13.9%; Headache
Arthralgia, 2%; Chest
and runny nose, 4%; Sore
9.4%;Headache,
, 13.6%; Chills, 11.5%;
pain, 2%
throat, 6%; Nausea and
6.5%;Vomiting, 3.6%;
Nausea or vomiting, 5%;
vomiting, 6%)
Abdominal pain, 2.2%
Nasal congestion , 4.8%;
Diarrhea , 3.8%; other
1.7%;

*At chest CT, GGOs were bilateral in 88% of patients, involving the posterior lungs in 82% and the peripheral lungs in 85% of patients. Patients older than 50 years had more
consolidated lung lesions than did those aged 50 years or younger (212 of 470 vs. 198 of 854; P: 0.001)
** Median duration from ICU admission to death was 7 (IQR 3–11) interquartile range.

11%

31%

ARDS, 17%;Acute
renal injury, 3%;Acute
respiratory injury,
8%; Septic shock, 4%
Ventilator-associated
pneumonia, 1%

ARDS, 29%; RNAemia,
15%;Acute cardiac injury,
12%; Acute kidney
injury,7%; Secondary
infection, 10%;Shock, 7%

Signs and
symptoms

NA

Fever, 83%; Cough, 82%;
Shortness of breath,
31%); Muscle ache,
11%; Confusion, 9%;
Fever, with or without
Headache, 8%); Sore
recorded temperature
throat, 5%; Rhinorrhea,
4%; Chest pain, 2%;
Diarrhea, 2%; Nausea
and vomiting, 1%

Fever, 98%; Cough, 76%;
Myalgia or fatigue, 44%);
Sputum production,
28%; Headache, 8%;
Hemoptysis, 5%
;Diarrhea, 3%; Dyspnea,
55%

Table 5. (Continued).
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among these patients were reported to be 55% and 34%,
respectively [68]. Similarly, a multi-variance analysis
established the factors that identify a poor prognosis at
an early stage as older age, high “sequential organ failure
assessment” (SOFA) score and D-dimer value > 1 μg/L
during hospitalization [6].
The COVID-19 differential diagnosis should be
differentiated for infectious and noninfectious reasons.
However, it should be noted that the COVID-19 infection
may accompany other viral or bacterial infections of
respiratory tract. In these cases, the agents of lower
and upper respiratory tract infection (influenza A and
B, respiratory syncytial virus, parainfluenza viruses,
rhinoviruses, adenoviruses, enteroviruses (e.g., EVD68),
human metapneumovirus and endemic human
coronaviruses (i.e. HKU1, OC43, NL63, and 229E)) should
be investigated. It is important to investigate the bacterial
agents leading to lower respiratory tract infections, such as
Legionella pneumophila, and to start therapy accordingly.
Differential diagnosis is used to investigate infections, such
as malaria, arbovirus infection (dengue/chikungunya),
etc., in endemic regions [61, 63,65,66].
Health professionals started to be infected nosocomially
in the early periods when there was scarce information
about the COVID-19 infection and its causative agent
SARS-CoV-2 with a multitude of unknown things. In
China, 14.6% of 1,688 health professionals diagnosed in
a laboratory setting were severe. However, the number
of cases among health professionals started to decrease
in time particularly due to training, their proper use of
personal protective equipment and hand hygiene practices.
Initial cases occurred from 1 to 10 January 2020 (20 cases)
and peaked with 1,036 cases from 21 to 31 January. They
were found to be 322 after 1 February (1). 20% of the
Italian health professionals were infected, some of whom
lost their lives unfortunately [56].
5. Laboratory findings
During the course of COVID-19, patients have pathological
modifications as indicated by different laboratory tests.
The publications regarding these modifications shown
by laboratory tests are gradually increasing in number.
A substantial amount of knowledge has accumulated
despite the still lacking very detailed conclusions, and the
conclusions from several studies have been started to be
evaluated and analyzed [69–78].
The disorders diagnosed upon hematological,
immunological and biochemical tests are those that are
usually diagnosed in hospitalized patients. The summary
information on the tests used in this context is given in
Table 6.
Laboratory tests provide guidance in risk assessment,
clinical monitoring and therapy decision-making
processes [69–72].
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5.1. Hematological tests
Complete blood count (Hemogram)
The observation was that there was no significant change
in hemoglobin levels of COVID-19 patients, with those
reported with a slight minor decrease [36]. Patients with
severe disease were found to have significantly lower
hemoglobin values than patients with mild conditions
[71].
The count of leukocytesmay be normal as follows;
leukocytosis (> 10,000 / microL) 2% –30%, and leukopenia
(<4000 / microL) 9%–31% [70].
Studies demonstrated that mild leukocytosis was
noted in those with severe disease symptoms, while there
was a significant increase in the number of patients who
died. The increased level of leukocytes is a parameter
that is indicative of clinical deterioration. Various studies
discovered, in addition to leukocytosis, an increase in
the count of neutrophils and a decrease in the count of
lymphocytes, monocytes and eosinophils [18].
Lymphopenia (lymphocyte count <1500 / microL)
was frequently detected on the hemogram (3%–83.2%)
[36, 69]. Lymphopenia is a very common symptom in
patients with severe progression of COVID-19 and in
patients who died. The said patients were observed to have
reduced count of CD4+ and CD8+ T cells. The percentage
of lymphocytes, along with the count of CD4 + and CD8 +
T cells, was proposed as a predictive biomarker for disease
severity or recovery (prognosis) [72]. The studies carried
out demonstrated that neutrophil to lymphocyte ratio in
patients with COVID-19 may be a significant marker in
explaining disease severity and mortality. Severe disease
and intensive care unit admission were significantly high
in the group of patients with the neutrophil-to-lymphocyte
ratio (NLR) of ≥3.13, and NLR was considered the
independent risk factor for the illness [73].
Additionally, thrombocytopenia (5%–36.2%) was
reported [18,69,70]. Moderate thrombocytopenia
is common, but rarely below 100,000/microL [74].
Platelet count was significantly low in patients with
severe COVID-19 course. Additionally, significant
thrombocytopenia was found in subjects who died than
survivors. Based on the conclusions from several studies,
it was noted at a 5-fold higher level in patients with
severe disease course. A low platelet count is linked to an
increased risk of severe disease and mortality in patients
with COVID-19, and is indicative of poor prognosis.
Patients showing signs of fluctuation in platelet count
or signs of heparin resistance should be considered for
heparin-induced thrombocytopenia (HIT) [69,74].
5.2. Coagulation tests
Patients with COVID-19 were observed to be prone to
coagulopathy. However, no adequate data is yet available
regarding bleeding and thrombosis. Furthermore,
coagulation tests are critical to the diagnosis and
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Table 6. Common laboratory findings among hospitalized patients with COVID-19*.
Tests

Changes and interpretations

Hematological parameters (including hemostasis and coagulation)

Complete blood count

Hemoglobin (usually normal, may be decreased in severe cases)
Wbc [normal, decreased (29%), increased (in ICU cases)]
Lymphopenia (in most cases), < 800 microL in severe cases
Eosinopenia (in most cases),
Thrombocyte (normal, increased, slightly lower in severe cases

CD4 and CD8

Decreased (in most cases)

PT and aPTT

Normal, slightly prolonged (in severe cases, especially in ICU cases)

Fibrinogen

Increased

D-dimer

Increased (in severe cases; in nonsurvivors); >1000 ng/mL in severe cases

Inflammatory markers
CRP

Increased (higher in severe cases); > 10 x the upper limit of normal (N: < 8 mg/L)

ESR

Normal, Increased

Ferritin

Increased (in severe cases); > 500 mcg/L (N: 10/30–200/300 mcg/L)

Procalcitonin

Normal, increased (in severe cases, secondary to bacterial pneumonia in ICU patients)

Il-6

Increased (according to severity: >critical>severe>mild; cytokine storm)

Biochemistry tests
Glucose

Increased (in severe cases)

BUN and creatinine

Increased (in severe cases)

Electrolytes

Hyponatremia, hypokalemia

Albumin

Decreased (in severe cases)

ALT and AST

Increased (especially in ICU cases)

Total bilirubin

Increased (in severe cases)

Lactate dehydrogenase

Increased (in severe cases, in ICU cases, in ARDS cases); >245 U /L in severe cases (N: 110–210 u/L)

Creatine phosphokinase

Increased in severe cases; > 2 x the upper limit of normal (N: 40–150 U/L)

Troponin T/I

Increased (in severe cases), > 2 x the upper limit of normal ( N: 0–9/14 ng/L)

NT-ProBNP

Increased (in severe cases)

*Adapted from resources 18,33,69,70–81.

assessment of disseminated intravascular coagulation,
which is an important complication noted in patients with
COVID-19 [18].
D-dimer: It was noted in 9%–43% of the patients
investigated [18]. The level of D-dimer at admission was
found to be associated with the risk of developing ARDS
the requirement for intensive care and the risk of mortality
[18,75]. The high D-dimer level and the D-dimer levels
significantly increased over time are associated with
high mortality, and may be marker of infection/sepsis,
cytokine storm and impending organ failure. In particular,
D-dimer levels in intensive care patients were noted to be
significantly higher than those in patients who were not
admitted to intensive care units [18].
Prothrombin time was significantly increased in
survivors and patients who died.

Disseminated intravascular coagulation in patients
with COVID-19 may develop over time due to poor
prognosis [72].
5.3. Cardiac tests
Type-B natriuretic peptide (BNP/NT-proBNP):
The rapidly increasing level of NT-proBNP related to
cardiac dysfunction in patients with severe COVID-19
was found to be significantly higher [36,70,76].
Cardiac troponins (TnTTnI): COVID-19 may lead
to serious inflammatory cases that are likely to enhance
thrombosis and myocardial infarction. Additionally,
viruses or inflammation may directly cause myocardial
damage. Serum troponin I levels were seen to be high in
critical COVID-19 patients (8%–51.2%;)[36,70].
At hospitalization, patients with COVID-19 (12.5%)
were found to have myocarditis-like abnormalities,
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especially an elevated level of cardiac troponin I. The
troponin level, which was normal at admission, increased
gradually over time (37.5%) (in the absence of typical
EKG and echography), especially in patients who died.
The elevation of cardiac troponin I is more associated with
systemic disorders [77].
Elevations in cardiac markers may originate from
secondary and systemic outcomes (multiple organ failure,
etc.) rather than the effect of the virus [36,70].
Creatine kinase (CK/CK-MB): The muscle-induced
creatine kinase provides an insight, especially into the
assessment of myocardial damage. CK-MB was found to
be high at 7%–33%; higher rates were noted in patients
with severe disease course [36,70].
Myoglobin: Myoglobin is commonly present in most
tissues, and the plasma level was found to have increased
by 25% to 17% in connection with the cardiac damage in
patients with COVID-19 [36,70].
5.4. Markers of inflammation
C-reactive protein (CRP): High levels of C-reactive
protein (CRP) were noted in the vast majority of COVID-19
patients (3%–91%) and shown to be associated with disease
severity [69,70,78]. CRP levels give an idea for disease
severity and prognosis. Additionally, it is considered to
be a potential early marker for sepsis and mortality. It is
suggested that CRP level, especially at admission, may be
critical for grading disease severity [78]. The patients who
survived had a CRP level of ~40 mg/L, while those who
died had 125 mg/L (60–160 mg/L) [74].
Non-COVID etiologies (such as heart failure) should
be considered for a patient with severe respiratory distress
and normal CRP levels.
Erythrocyte sedimentation rate (ESR): ESR, which
is specifically assessed together CRP in COVID-19 cases,
were generally found to be high (15%–85%) [36]. Patients
with severe and moderate COVID-19 were shown to have
elevated CRP and ESR without any modification indicated
by the lung CT scan [72]. ESR, along with CRP, could be an
important and inexpensive monitoring parameter.
Cytokines: Cytokines have critical effects on the
pathogenesis of the disease. Studies showed that IL6, IL-2, IL-10 and IFN levels were elevated. Especially,
hyperinflammation may lead to cytokine storm mediated
by IL-6 receptors.
Blood cytokines and chemokines were found to
be present at significantly high levels in patients with
COVID-19 infection, including IL1-β, IL1RA, IL7, IL8,
IL9, IL10, FGF2, GCSF, GMCSF, IFNy, IP10, MCP1,
MIP1α, MIP1β, PDGFB, TNFa and VEGFA [76]. Some
of the severe subjects presenting to the intensive care
unit were noted to have high levels of proinflammatory
cytokines, including IL2, IL7, IL10, GCSF, IP10, MCP1,
MIP1α and TNFα, which were justified for the increased
disease severity [18,76].
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Ferritin: Ferritin becomes elevated as an outcome
of the activation of macrophages and hepatocytes in
COVID-19 cases. Unlike other viral infections, ferritin is
elevated at a moderate level in cytokine storm syndrome.
It is thought to be used as a predictive marker of sepsis
mortality [69, 70].
Procalcitonin: The level of procalcitonin in COVID-19
usually remains within the normal range at admission
(<0.5 in 95% of the patients) [33]; however, it is likely that
this level could be higher in patients who need admission
to ICU (3%–35%) [69].
Few studies found increased procalcitonin levels.
This should primarily suggest an alternative diagnosis
(bacterial pneumonia); however, any progressive PCT
increase in patients who are hospitalized/admitted to ICU
may be associated with this poor prognosis or a secondary
bacterial infection [18,27,75].
Patients with elevated PCT were noted to have a 5-fold
more severe COVID-19 infection risk (OR, 4.76; 95% CI,
2.74–8.29) [69].
5.5. Biochemical tests
COVID-19 leads to important modifications indicated by
biochemical tests since it affects various systems.
Albumin:
Albumin is low in especially about 50% of the patients
with prolonged clinical course. The studies conducted
with COVID-19 patients suggest that low serum albumin
levels are linked to the increased risk of mortality [69,70].
Albumin concentrations were significantly lower
in severe cases compared to moderate cases, where
hypoalbuminemia (albumin <32 g/L) were seen more
frequently in severe cases [76].
Glucose: COVID-19 patients with diabetes are exposed
to high risk of progressing to ARDS, septic shock and
multiple organ failure. Retaining glucose level within the
normal range in this patient group is one of the parameters
to be noted for comorbidity [69, 70].
Aminotransferases: Studies have indicated increases
in ALT (17%–28%), AST (8%–37%) and gamma-glutamyl
transferase levels which are over 3-fold higher than the
upper limit [70]. There is no direct association found
between the rate of increase in enzymes and the severity of
the disease. Liver damage increases upon the prolongation
of hospitalization, which could be associated with therapy
protocols [79]. Abnormalities indicated by liver tests were
noted to be higher in patients who developed pneumonia
over time. Alanine aminotransferase (ALT) and aspartate
aminotransferase (AST) levels were significantly higher in
severe cases than in moderate cases [76,79].
Total bilirubin: Bilirubin increased by 0%–18%
(generally up to 3-fold the upper limit) associated with
hepatocellular damage and cholestatic liver diseases could
be seen in COVID-19 patients [69,70].
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Lactate dehydrogenase (LDH): Studies have shown
high LDH levels, ranging from 27% to 76%, in patients
[69,70]. High LDH levels in patients with severe COVID-19
are considered to be a potential marker that indicates lung
injury and tissue damage. In one of the studies conducted,
it was observed that advanced age, hypertension and high
LDH levels at admission were associated with the elevation
in hospital mortality rates. LDH was higher in severe cases
than in mild and moderate cases [76].
Kidney function tests (BUN and creatinine):
COVID-19 may cause damage to kidney cells. It
was observed, during research studies, that BUN and
creatinine levels (3%–17%) were usually high and the
glomerular filtration rate was also reduced (<60 mL/min).
During hospitalization, patients were observed to have
increased creatinine accompanied by higher proteinuria
and hematuria levels [80].
Electrolytes: In general, low concentrations of plasma
sodium, potassium and calcium were reported, but no
clarification was provided on whether this is a high risk
for COVID-19. A study found higher serum potassium
levels in patients who died of COVID-19 than those who
recovered [81].
5.6. Severity indicators, poor prognosis criteria
Various laboratory characteristics of hospitalized patients
with COVID-19, amongst common laboratory findings
including lymphopenia, high aminotransaminase levels,
high lactate dehydrogenase levels and high inflammatory
marker levels, high D-dimer levels and more severe
lymphopenia, were associated with mortality [69].
Severity indicators and poor prognosis criteria are
shown in Table 6.
Patients who were higher in these values or some of
these values (D-dimer, procalcitonin, etc.) (Lippi G) were
over 3 times more admitted to intensive care. Mortality
rates were very high in the group of patients with DIC
criteria (deceased 71.4%, survivors 0.6%) [69].
D-dimer, serum ferritin, troponin I, LDH, Pa02<90
mmHg and IL-6 levels, which were high at initial diagnosis
or were elevated during monitoring, were defined as
“poor prognostic factors” associated with severe disease
and mortality [18,27,76]. Especially in cases of severe
pneumonia, the monitoring of these parameters was
proven to be beneficial in “cytokine storm” and progress to
ARDS caused by the over-triggered immune system [18,
27, 74–76].
The elevated D-dimer and fibrinogen degradation
products and the prolonged prothrombin time were

associated with poor prognosis in patients with
COVID-19 [34].
COVID-19 patients were noted to have high
interleukin (IL)-6 and IL-10 levels and low CD4 + T and
CD8 + T cell levels associated with disease severity [82].
D-dimer, serum ferritin, troponin I, LDH, Pa02<90
mmHg and IL-6 levels, which were high at initial
diagnosis or were elevated during monitoring, were
defined as “poor prognostic factors” associated with
severe disease and mortality [18,27,76]
D-dimer, fibrinogen, platelet count, lactate
dehydrogenase (LDH), creatine and alanine
aminotransferase (ALT) values should be monitored on
a daily basis or 2–3 times per week.
In conclusion, laboratory tests are vital to determine
the severity and prognosis of the disease, along with the
condition and exposure of the affected systems during
the course of COVID-19. These are guiding elements
of risk assessment, clinical monitoring and therapy
decision-making processes. Depending on the severity
of the disease, some patients should be monitored
regularly on a daily basis.
6. Conclusion
Both the viral particle and the virus-induced
exaggerated immune response play an important role in
the pathogenesis of COVID-19.
The significant effect of genetic polymorphism on
the course and severity of the COVID-19 has not been
proven yet.
The disease progress with various symptoms, such
as fever, cough, dyspnea, malaise, myalgia, taste and
smell dysfunctions, diarrhea, and headache. The disease
is mild in most cases; in some cases (usually regarding
the elderly and those with comorbidities), various
complications could be seen during the course of the
disease.
Varied laboratory tests are guiding elements of risk
assessment, clinical monitoring and therapy decisionmaking processes.
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